Navigation Links
CNBC, Discovery Channel and National Geographic to Cover Dr. Robert Melamede and Richard Cowan of Cannabis Science Whom are Speaking at 'The Marijuana Conference' in New York City on Oct. 25 & 26

COLORADO SPRINGS, Colo., Oct. 21 /PRNewswire/ -- Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the upcoming coverage by CNBC, Discovery Channel and National Geographic for the speaking engagement of Dr. Robert Melamede, Cannabis Science, Inc., President & CEO, along with panelist discussions with Richard Cowan, Cannabis Science, Inc., Director & CFO, at "The Marijuana Conference" in New York City.  

The Marijuana Conference (, organized by Dealflow, will take place October 25 & 26. It is being called "the first non-biased event in the industry." It will "cover all of the business and investment issues, and the pros and cons of legalization, offering in-depth analysis from a wide array of experts."

Film crews from CNBC, Discovery Channel and National Geographic will be in attendance, and will be filming and using footage from the event in upcoming documentaries about the industry.

Dr. Melamede noted, "It is with great pleasure that I can participate in this convention. As November 2 approaches, this national exposure will help the greater cause of legalization of medical marijuana and the ending of decades of ignorance and unwarranted fear as the value of medical marijuana is rediscovered and supported by thousands of peer reviewed scientific articles and the personal experience of hundreds of thousands of medical marijuana users".

CNBC anchor Trish Regan has been added to the agenda as the moderator for the panel discussion titled "Entrepreneurial Vision: The Business of Marijuana".  Richard Cowan, Cannabis Science CFO, will be one of the panelists.

Richard Cowan, Cannabis Science CFO, commented "This conference is an excellent opportunity to introduce Cannabis Science to the New York financial community."

Ms. Regan is the host of the CNBC documentary "Marijuana Inc." and the upcoming sequel. CNBC will be covering the event as part of the documentary.

Other speakers include:

  • Stephen D'Angelo, Executive Director, Harborside Health Center
  • Lester Grinspoon, MD, Associate Professor Emeritus of Psychiatry, Harvard Medical School
  • Trish Regan, CNBC Anchor, Host of "Marijuana Inc."
  • Andrea Barthwell, Former Deputy Director for Demand Reduction, Executive Office of The President
  • Jill Lamoureux, Boulder County Caregivers & CDS Management Services
  • Joel W. Hay, PhD, Professor of Pharmaceutical Economics & Policy, University of Southern California
  • Senator Joshua Miller (D), Rhode Island State Senate
  • Jeffrey A. Miron, Director of Undergraduate Studies, Department of Economics, Harvard University
  • David E. Smith MD. Founder, Haight Ashbury Free Medical Clinic 

  • About Cannabis Science, Inc.Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

    Forward Looking StatementsForward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.Cannabis Science, Inc.

    Dr. Robert J. Melamede
    President & CEO
    1-888-889-0888Cannabis Science, Inc.

    Mark J. Friedman

    Investor Relations
    1-877-431-CBIS (2247)

    SOURCE Cannabis Science, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
    2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
    4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
    5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
    6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
    7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
    8. FASgen Announces New Discovery for Treatment of Stroke
    9. Nobel Prize-Winning Discovery
    10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
    11. FASgen Announces a New Discovery in Obesity Research
    Post Your Comments:
    (Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
    (Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
    (Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
    Breaking Medicine Technology:
    (Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
    (Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
    (Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
    (Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
    (Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
    Breaking Medicine News(10 mins):